Paper Details

  1. Home
  2. Paper Details

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.

Author: BockT, BrunsI, BökerK H, CondreayL D, GauthierJ, GlowienkaM, JäckelE, MannsM P, OldhaferK, RaabH R, TillmannH L, TrautweinC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Lamivudine (LAM) was effective in reducing HBV-DNA levels in patients with recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT) who had insufficient response to famciclovir (FCV). However, LAM breakthrough was associated with the M552V mutation in the YMDD motif of the HBV-DNA polymerase gene. FCV breakthrough was associated with the L528M mutation. The L528M mutation was a risk factor for LAM breakthrough, with breakthrough occurring earlier in patients with this mutation.
Paper Details　
Original Abstract of the Article :
Famciclovir (FCV) and lamivudine (LAM) reduce viral replication in patients with recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). Eighteen of 20 patients with insufficient response to FCV were treated with 100 mg LAM daily after OLT. These patients had shown ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/hep.510300141

データ提供：米国国立医学図書館（NLM）

Hepatitis B Virus Reinfection After Liver Transplantation: A Complex Challenge

Treating hepatitis B virus (HBV) reinfection after liver transplantation is a complex endeavor, akin to navigating a shifting desert landscape where the terrain is constantly changing. This study examines the effectiveness of sequential therapy with famciclovir (FCV) and lamivudine (LAM) in patients with HBV reinfection. The researchers found that while both drugs initially reduced viral replication, resistance mutations emerged, leading to treatment failure in many patients. This highlights the need for proactive strategies to manage HBV reinfection and prevent the development of drug resistance.

A Shifting Landscape of Resistance

This research underscores the challenge of managing HBV reinfection in liver transplant patients. The emergence of drug resistance mutations emphasizes the need for innovative treatment approaches and careful monitoring to prevent treatment failure. This underscores the dynamic nature of viral infections and the need for adaptive treatment strategies.

Navigating the Desert of Viral Resistance

Just like a desert traveler needs to adapt to changing conditions, healthcare providers must be prepared to adjust treatment strategies in response to emerging viral resistance. This study highlights the importance of proactive management and innovative approaches to prevent treatment failure in patients with HBV reinfection.

Dr.Camel's Conclusion

This research provides valuable insights into the complexities of HBV reinfection after liver transplantation. It emphasizes the need for ongoing research into new treatment strategies and monitoring methods to combat drug resistance and improve patient outcomes. Like a desert explorer seeking to map uncharted territory, researchers are continuously seeking to better understand and manage HBV reinfection in liver transplant patients.

Date :
  1. Date Completed 1999-07-29
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

10385663

DOI: Digital Object Identifier

10.1002/hep.510300141

Related Literature

Article Analysis
・Side Effects of famciclovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.